Christiane Pott, Vindi Jurinovic, Judith Trotman, Britta Kehden, Michael Unterhalt, Michael Herold, Richard van der Jagt, Ann Janssens, Michael Kneba, Jiri Mayer, Moya Young, Christian Schmidt, Andrea Knapp, Tina Nielsen, Helen Brown, Nathalie Spielewoy, Chris Harbron, Alessia Bottos, Kirsten Mundt, Robert Marcus, Wolfgang Hiddemann, Eva Hoster
PURPOSE: We report an analysis of minimal residual/detectable disease (MRD) as a predictor of outcome in previously untreated patients with follicular lymphoma (FL) from the randomized, multicenter GALLIUM (ClinicalTrials.gov identifier: NCT01332968) trial. PATIENTS AND METHODS: Patients received induction with obinutuzumab (G) or rituximab (R) plus bendamustine, or cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or cyclophosphamide, vincristine, prednisone (CVP) chemotherapy, followed by maintenance with the same antibody in responders...
February 10, 2024: Journal of Clinical Oncology